Vagilak capsules bottle No. 10

Instructions for Vagilak capsules bottle No. 10

Composition

active ingredient: 1 capsule contains 4 billion active cells (CFU) of Lactobacillus acidophilus, Lactobacillus rhamnosus, Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus;

excipients: lactose monohydrate; magnesium stearate; ascorbic acid;

capsule shell: gelatin.

Dosage form

Vaginal capsules.

Main physicochemical properties: creamy gelatin capsules containing white or ivory-colored powder, the presence of individual darker granules is allowed.

Pharmacotherapeutic group

Other means used in gynecology.

ATX code G02C X.

Pharmacological properties

Pharmacodynamics

Lactobacilli, which predominate in the normal vaginal flora, are a natural barrier to infections. These microorganisms contribute to the regulation of the vaginal microbiota by competitively binding to vaginal epithelial cells and producing antimicrobial compounds. The family Lactobacillaceae includes gram-positive, mostly immobile microorganisms, facultative anaerobes that do not form spores, have the ability to ferment, ferment carbohydrates with the formation of lactic acid, which prevents the reproduction of pathogenic and conditionally pathogenic microflora. This is a morphologically heterogeneous group of bacteria that includes long and short rods, as well as cocci.

Lactic acid streptococcus creates conditions for the development of lactic acid bacilli, reducing the redox potential to a value favorable for their development. Lactic acid bacilli, in turn, produce a water-soluble thermostable compound that promotes the growth of streptococci and which they themselves cannot produce. The symbiotic relationships that exist between lactic acid bacilli and cocci are an important and necessary condition for the inclusion of these microorganisms in the composition of the drug Vagilak, which is used for the prevention and treatment of vaginal dysbacteriosis of various origins. Lactobacteria assimilate glycogen, which is found in the cells of the vaginal squamous epithelium, and through anaerobic glycolysis secrete lactic acid, which causes a weakly acidic reaction (pH 4.3–4.7) of the vaginal contents. Due to this, lactic acid bacteria play an important role in maintaining and normalizing the microbial balance of the vaginal mucosa, preventing the development of pathogenic and conditionally pathogenic microflora, and promoting self-cleansing of the vagina from conditionally pathogenic flora.

Pharmacokinetics

The drug is not absorbed from the vagina, therefore it does not have a systemic effect on the body. The colonization ability of lactobacilli, which are part of the drug Vagilak, is enhanced by the combination with Streptococcus thermophilus.

Indication

Prevention and treatment as part of complex therapy of vaginosis of various origins (trichomonas, bacterial, fungal).

Contraindication

History of hypersensitivity to the drug or its components. Widespread acute inflammatory (purulent) and erosive changes in the vaginal mucosa.

Interaction with other medicinal products and other types of interactions

The drug can be prescribed in complex therapy together with antibiotics, sulfonamides, metronidazole, and other antibacterial drugs.

Ability to influence reaction speed when driving vehicles or other mechanisms

Vagilak does not affect the reaction speed when driving vehicles or other mechanisms.

Use during pregnancy or breastfeeding

Vagilak can be used by women during pregnancy and breastfeeding.

Method of administration and doses

The drug is intended for vaginal use.

Use for treatment purposes.

For the treatment of acute, chronic, recurrent infectious and inflammatory diseases of the genital organs in women, Vagilak is prescribed a few days after the start of antibacterial therapy (on the 4th-5th day), and also, if necessary, after its completion. Duration of use - 10 days. 1 capsule at night. While lying down, insert the capsule deep into the vagina.

Use for prevention purposes.

For the prevention of diseases of the reproductive system in women (bacterial vaginosis, candidiasis, trichomoniasis), Vagilak is used from the beginning of the second half of the menstrual cycle for 5 or 10 days. While lying down, insert the capsule deep into the vagina. 1 capsule at night.

Children

The drug is not used in children.

Overdose

Impossible.

Adverse reactions

Hypersensitivity reactions are possible; injection site reactions, including redness and burning.

Expiration date

3 years.

Storage conditions

Store out of the reach of children at a temperature of 2 to 8 ºC.

Packaging

10 capsules per bottle.

Vacation category

Without a prescription.

Producer

Pharmascience Inc.

Location of the manufacturer and its business address

6111 100 Royalmount Avenue, Montreal, Quebec H4R 2T4, Canada.